Adial Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2834 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations - Dec 3rd, 2024 1:30 pm
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - Dec 3rd, 2024 1:00 pm
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - Nov 25th, 2024 5:00 pm
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Nov 14th, 2024 1:30 pm
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - Nov 14th, 2024 1:00 pm
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 13th, 2024 1:30 pm
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - Nov 5th, 2024 1:30 pm
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - Oct 23rd, 2024 1:00 pm
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment - Oct 17th, 2024 1:00 pm
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - Oct 17th, 2024 12:30 pm
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - Oct 15th, 2024 1:00 pm
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Sep 19th, 2024 12:30 pm
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 1:00 pm
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 14th, 2024 12:30 pm
Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04 - Aug 13th, 2024 1:00 pm
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder - Aug 13th, 2024 12:30 pm
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Aug 7th, 2024 1:00 pm
EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4 - Aug 7th, 2024 12:30 pm
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 - Jul 31st, 2024 12:30 pm
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Jul 23rd, 2024 12:30 pm